Wei Tzu-Tang, Lin Yu-Chin, Lin Pei-Hua, Shih Jin-Yuan, Chou Chia-Wei, Huang Wei-Jan, Yang Yu-Chih, Hsiao Pei-Wen, Chen Ching-Chow
Department of Pharmacology, College of Medicine, National Taiwan University, Taipei, Taiwan.
Department of Internal Medicine, Far-Eastern Memorial Hospital, New Taipei, Taiwan.
Oncotarget. 2015 May 20;6(14):12481-92. doi: 10.18632/oncotarget.3489.
Here we found loss of c-Cbl, an E3 ligase, expression in non-small cell lung cancer (NSCLC) compared with its adjacent normal tissue in patient specimens. HDAC inhibition by WJ or knockdown of HDAC 1, HDAC2, HDAC3 or HDAC6 all induced c-Cbl. Ectopic expression of c-Cbl induced decreased EGFR, inhibited growth in NSCLC cells. Knockdown of EGFR inhibited NSCLC growth. Mutation of EGFR at Y1045 decreased WJ-induced growth inhibition as well as in vivo anti-cancer effect and EGFR degradation mediated by WJ. Time-lapse confocal analysis showed co-localization of c-Cbl and EGFR after WJ treatment. Furthermore, WJ inhibited lung tumor growth through c-Cbl induction in orthotopic and tail vein injected models. C-Cbl up-regulation induced by HDACi is a potential strategy for NSCLC treatment.
在此我们发现,在患者标本中,与非小细胞肺癌(NSCLC)相邻的正常组织相比,E3连接酶c-Cbl的表达缺失。WJ对组蛋白去乙酰化酶(HDAC)的抑制作用或HDAC 1、HDAC2、HDAC3或HDAC6的敲低均诱导了c-Cbl的产生。c-Cbl的异位表达导致表皮生长因子受体(EGFR)减少,抑制了NSCLC细胞的生长。EGFR的敲低抑制了NSCLC的生长。EGFR在Y1045处的突变降低了WJ诱导的生长抑制作用以及体内抗癌效果和WJ介导的EGFR降解。延时共聚焦分析显示,WJ处理后c-Cbl与EGFR共定位。此外,在原位和尾静脉注射模型中,WJ通过诱导c-Cbl抑制了肺肿瘤的生长。HDAC抑制剂诱导的C-Cbl上调是一种潜在的NSCLC治疗策略。